Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M F Sarosdy

Showing results (1-10 of 66) with videos related to

Pageof 7
Sort By:
Anti-Cancer Drugs|December 10, 1999
Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogenM F Sarosdy
The Urologic Clinics of North America|August 1, 1992
Principles of intravesical chemotherapy and immunotherapyM F Sarosdy
Urology|August 1, 1992
Continent urinary diversion using cutaneous ileocecocystoplastyM F Sarosdy
European Urology|January 1, 1997
Oral bropirimine immunotherapy of rodent prostate cancerM F Sarosdy
The Urologic Clinics of North America|May 1, 1992
Management of the male urethra after cystectomy for bladder cancerM F Sarosdy
Annals of the New York Academy of Sciences|June 23, 1993
Bropirimine in bladder cancer: clinical studiesM F Sarosdy
World Journal of Urology|January 1, 1997
The use of the BTA Test in the detection of persistent or recurrent transitional-cell cancer of the bladderM F Sarosdy
European Urology|January 1, 1997
A review of clinical studies of bropirimine immunotherapy of carcinoma in situ of the bladder and upper urinary tractM F Sarosdy
The Journal of Urology|November 20, 1997
Data interpretation and integration of new tests into clinical practiceM F Sarosdy
The Journal of Urology|January 1, 1997
The significance of central pathology review in clinical studies of transitional cell carcinoma in situF E Sharkey, M F Sarosdy
Pageof 7

Showing results (1-10 of 66) with videos related to

Sort By:
Pageof 7
Anti-Cancer Drugs|December 10, 1999
Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogenM F Sarosdy
The Urologic Clinics of North America|August 1, 1992
Principles of intravesical chemotherapy and immunotherapyM F Sarosdy
Urology|August 1, 1992
Continent urinary diversion using cutaneous ileocecocystoplastyM F Sarosdy
European Urology|January 1, 1997
Oral bropirimine immunotherapy of rodent prostate cancerM F Sarosdy
The Urologic Clinics of North America|May 1, 1992
Management of the male urethra after cystectomy for bladder cancerM F Sarosdy
Annals of the New York Academy of Sciences|June 23, 1993
Bropirimine in bladder cancer: clinical studiesM F Sarosdy
World Journal of Urology|January 1, 1997
The use of the BTA Test in the detection of persistent or recurrent transitional-cell cancer of the bladderM F Sarosdy
European Urology|January 1, 1997
A review of clinical studies of bropirimine immunotherapy of carcinoma in situ of the bladder and upper urinary tractM F Sarosdy
The Journal of Urology|November 20, 1997
Data interpretation and integration of new tests into clinical practiceM F Sarosdy
The Journal of Urology|January 1, 1997
The significance of central pathology review in clinical studies of transitional cell carcinoma in situF E Sharkey, M F Sarosdy
Pageof 7